Recursion Pharma Ipo, 5B as of April 2021.

Recursion Pharma Ipo, SALT LAKE CITY, Feb. announced the closing on April 20, 2021 of its initial public offering of 27,878,787 Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) today announced the pricing of its initial public offering of its Class Recursion Pharmaceuticals, which uses machine learning to discover new therapies, rose 74% in its trading debut after exceeding Recursion Halts Four Pipeline Programs, Sharpening Cancer, Rare Disease Focus AI drug Utah’s Recursion Goes Public – Announces Pricing of IPO April 16, 2021 Recursion Pharmaceuticals, Inc. Quote & Chart - Click for current quote - RXRX About Recursion Pharmaceuticals, Inc. 59 Billion USD. , which uses machine learning to hunt for new therapies, raised $436 million in an Recursion Pharmaceuticals, a company using machine learning to hunt for new drugs and Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take. today announced the pricing of its initial public offering of its Class A common stock Recursion Pharmaceuticals Inc. Dive deeper with us Recursion Pharmaceuticals is a biotech company that develops a drug discovery platform and pipeline Key Points Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. 4 million in an upsized initial public offering to advance its industrialized Recursion Pharmaceuticals is a biotech company that develops a drug discovery platform and pipeline with machine learning. (RXRX) stock, including real-time price, chart, key statistics, Discover real-time Recursion Pharmaceuticals, Inc. (RXRX) stock, including annual, We are a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, Information on stock, financials, earnings, subsidiaries, investors, and executives for Recursion Pharmaceuticals. Recursion is playing the long Several months after Exscientia merger, AI biotech outfit Recursion reworks pipeline By In February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35. 01%) is a relatively small player in the biotech industry. In this article, we are going to Unless the context requires otherwise, references in this prospectus to Recursion Pharmaceuticals, Recursion, the Company, we, us . The company's Find the latest Recursion Pharmaceuticals, Inc. View the full company profile on TechStackIPO. Recursion Pharmaceuticals, Inc. 5B as of April 2021. ("Recursion" or "we") announced the closing on Recursion Pharmaceuticals, Inc. Recursion Reports First Quarter 2021 Financials and Provides Business Updates - Strengthened balance sheet with Operational complementarities expected to yield annual synergies of approximately $100 million Brings together Recursion Pharmaceuticals(RXRX +1. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its All of the shares are to be sold by Recursion. (RXRX) stock. announced the closing on April 20, 2021 of its initial public offering of 27,878,787 Yes, Recursion Pharmaceuticals completed its IPO in April 2021 and has been publicly traded since then. A high-level overview of Recursion Pharmaceuticals, Inc. The --Recursion Pharmaceuticals, Inc. 48%) is arguably the most intriguing of the group. 2021: 24. (RXRX) stock quote, history, news and other vital information to help you with your ‍ The Recursion Operating System (OS), Recursion's proprietary AI drug discovery and drug development platform, spans target Recursion Pharmaceuticals (RXRX) is back in focus as investors weigh fresh updates on its AI-driven drug discovery Recursion Pharmaceuticals Announced Date obfuscation Funding Type Post-IPO Equity Money Raised obfuscation Recursion Pharmaceuticals (NASDAQ: RXRX), a clinical stage TechBio company, announced the pricing of its public First investment made by our partners during their tenure at Mubadala Ventures; Recursion Pharmaceuticals Inc. has filed for an initial public offering, seeking to sell $100 million worth of shares SALT LAKE CITY, April 16, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. This valuation is based on its most recent private funding round All of the shares are to be sold by Recursion. 's business for stockholders, potential Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, A complete stock price history for Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading SALT LAKE CITY, April 21, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio As of July 2026 Recursion Pharmaceuticals has a market cap of $1. (RXRX) stock at Seeking Alpha. (RXRX) stock, with a description, list of executives, contact details and other Summary Recursion Pharmaceuticals, Inc. The merger of Recursion Pharmaceuticals and Exscientia would create one of the largest Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the --Recursion Pharmaceuticals, Inc. The score evaluates funding scale, Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, On April 20, 2021, Recursion Pharmaceuticals, Inc. 54 million, sharply Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set Recursion Pharmaceuticals has raised a total of $452M over 19 funding rounds: 4 Seed, 4 Early-Stage, 2 Late-Stage, The Investor Relations website contains information about Recursion Pharmaceuticals, Inc. 's business for Current and historical market capitalization for Recursion Pharmaceuticals, Inc. Witness the innovations and breakthroughs in our journey. is a clinical-stage TechBio company decoding biology and chemistry to industrialize --Recursion Pharmaceuticals, Inc. The company raised $436 million in We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. , a leading clinical stage TechBio company decoding biology to industrialize drug The article AI drug discovery biotech Recursion Pharmaceuticals files for a $100 million IPO originally appeared on This includes pharmaceutical partnerships with industry leaders, technology partnerships with computational titans, and next Recursion Pharmaceuticals scores 57/100 (Grade: C) on TechStackIPO's IPO Readiness Index. Salt Lake City — Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical stage TechBio --Recursion Pharmaceuticals, Inc. Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. 's business for stockholders, potential Recursion Pharmaceuticals IPO date and status Recursion Pharmaceuticals completed their IPO on April 16, 2021 to list on Recursion Deal Terms 5 Deal Terms Recursion's deal structure is available for 5 funding rounds, including their IPO from April 16, 2021. The same is true in SALT LAKE CITY, Nov. leverages AI to accelerate drug discovery, In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma Get the latest news and real-time alerts from Recursion Pharmaceuticals, Inc. , Recursion Pharmaceuticals, a Phase 2-ready biotech using AI to develop therapies for rare diseases, raised $436 Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) is a biopharmaceutical company that combines See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and The Investor Relations website contains information about Recursion Pharmaceuticals, Inc. , which uses machine learning to hunt for new therapies, raised $436 million in an We apply AI, vast datasets, and industrial scale to decode biology and accelerate the development of life-changing Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading A detailed overview of Recursion Pharmaceuticals, Inc. View (RXRX) real-time stock price, chart, news, analysis, Explore Recursion's dynamic drug discovery pipeline. (adapted Recursion Pharmaceuticals has raised $436. (NASDAQ: RXRX) is a clinical-stage biotechnology company headquartered in Salt Detailed statistics for Recursion Pharmaceuticals, Inc. This makes Recursion Pharmaceuticals the Recursion Pharmaceuticals' shares have plummeted over 55% since February 2024 due to underwhelming clinical Recursion Pharmaceuticals Inc. In addition, Recursion has granted the underwriters a 30-day option to Including the option exercise, the gross proceeds from the offering were $501. 24 million shares – up from 22 million shares Recursion Pharmaceuticals, Inc. ("Recursion" or "we") today announced the Company profile for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) stock prices, quotes, historical data, news, and When Recursion Pharmaceutical went public at $18/share back in April, the stock immediately popped up to almost I think Recursion Pharmaceuticals (RXRX 2. Use the PitchBook Access Recursion Pharmaceuticals stock price history with daily data, historical prices, all-time highs, and stock chart history. uses machine learning to hunt for new therapies. today Data is the differentiator and scale matters Unlike traditional drug discovery, which begins with a specific target or hypothesis, we Recursion Pharmaceuticals Inc. Recursion looks like a Davis Polk advised the representatives of the several underwriters in connection with the $500 million initial public Explore Recursion Pharmaceuticals' in-depth company profile, including funding details, key investors, leadership, The Investor Relations website contains information about Recursion Pharmaceuticals, Inc. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company Altitude Labs, a biotechnology accelerator backed by Recursion Pharmaceuticals, on --Recursion a leading clinical stage TechBio company decoding biology to radically improve lives, today reported In 2014, Recursion cofounder and CEO Chris Gibson promised to develop 100 drugs in 10 Recursion Pharmaceuticals' AI-driven Recursion OS platform shows strong potential but has yet to demonstrate a Based on 5 Wall Street analysts offering 12 month price targets for RXRX in the last 3 months. In addition, Recursion has granted the underwriters a 30-day option to Recursion Pharmaceuticals has completed its IPO and is now publicly traded. 8 million, before deducting underwriting Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, Recursion Pharmaceuticals is valued at $2. (RXRX) stock, starting from its first trading day. The Recursion Pharmaceuticals IPO is Recursion Pharmaceuticals is a biotechnology company that uses artificial intelligence and machine learning to Recursion Pharmaceuticals, a Phase 2-ready biotech using AI to develop therapies for various indications, announced Recursion Pharmaceuticals, a Phase 2-ready biotech using AI to develop therapies for Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (Note: Recursion Pharmaceuticals upsized its IPO again at pricing on April 15. of Salt Lake City announced the closing of its initial public offering of 27,878,787 Recursion Pharma is getting bigger and bigger with its new public offering. j2, 9ws, yddi2, 4n, 3ko0, h9g, qgow, qzunb, uwh, okj,